

FREDUN PHARMACEUTICALS LIMITED

Compassionate Healthcare

CIN No: L24239MH1987PLC043662



Date: 04th August, 2023

To,
BSE Ltd.,
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street - Fort,
Mumbai - 400 001

Scrip Code: 539730

Dear Sir/ Madam,

Sub.: Press Release issued by Fredun Pharmaceuticals Limited

Please find enclosed press release titled "**Fredun Pharmaceuticals achieves a remarkable milestone in Pet Care Division**" issued by Fredun Pharmaceuticals Limited.

Kindly take the same on your records and acknowledge the receipt.

Thanking you,

Yours truly,

For Fredun Pharmaceuticals Limited

Jinkal Soni
(Jinkal Shah)
Company Secretary and Compliance Officer

Registered Office: Urmi Estate, 11th Floor, Ganpatrao Kadam Marg, Lower Parel (W), Mumbai - 400013.

Phone No.: 91-22- 4031 8111 Fax: 91-22-4031 8133

Factory: 14,15,16, Zorabian Industrial Complex, Vevoor, Palghar (E), Dist: Palghar - 401 404.

Phone No.: +917045957828, +917045957829, +917045957830, +917045956857

E-Mail: business@fredungroup.com Web: www.fredungroup.com





FREDUN PHARMACEUTICALS LIMITED

Press Release
For Immediate Dissemination

PRESS RELEASE

Fredun Pharmaceuticals achieves a remarkable milestone in Pet Care Division

Mumbai, India | July 31, 2023

Fredun Pharmaceuticals Limited (BSE: 539730), a leading healthcare and pharmaceuticals company, proudly announces a momentous achievement in Freossi, its Pet care division, that has been receiving an extremely positive response and went completely stock out among the distributor channels. With this, the Company's annual run rate in the segment for FY24 stands at Rs. 20 crores.

With unyielding dedication and strategic planning, the company achieved 100% capacity utilisation in the division. These accomplishments stand as a testament to the company's dedication and vision.

The remarkable achievement not only bolsters Fredun Pharma's competitive edge in this segment but also demonstrates its unwavering resolve to cater to the escalating demands of the market. The company has received an overwhelming response and positive feedback from its trade channels, reinforcing its belief in the potential of Freossi's offerings. This has created a stock-out situation at trade channels, which is a testimony for company's innovative products. As a result, Fredun Pharmaceuticals anticipates an exceptional growth trajectory, projecting to double the Pet division's turnover next year.

Commenting on the milestone achievement, Mr. Fredun Medhora, Managing Director of Fredun Pharmaceuticals said, "We are ecstatic with the initial response we have received for our pet care brand Freossi. It is establishing a strong presence pan India and becoming a preferred brand for most veterinarians. The pet sector in India is completely dominated by the MNCs. Fredun Pharma, with its high-quality products and backward integration advantage, aims to be a significant pet player over the next five years."

Fredun Pharmaceuticals Limited remains committed to advancing its pet care division, striving to set new industry standards, and become a leading force in the pet care segment. With an unwavering focus on customer satisfaction, innovative products, and strong market presence, the company is well-poised for continued success and growth.



FREDUN PHARMACEUTICALS LIMITED

About Fredun Pharmaceuticals

Fredun Pharmaceuticals Limited, healthcare and pharmaceuticals company offer a range of products, including antihypertensives, antidiabetic, antiretroviral drugs (ARVs) and narcotics. It is also engaged in the manufacturing of dietary/herbal supplements, nutraceuticals, cosmeceuticals, and other healthcare products along with animal healthcare products. With such a diverse range of products, the Company's objective is to be a holistic healthcare provider. The Company primarily exports its products to Africa, Southeast Asia, Commonwealth of Independent States (CIS) countries and Latin America.

For further details, please feel free to contact:

Investor Relations team at Fredun Pharmaceuticals Limited

Fredun Medhora

Managing Director, Fredun Pharmaceuticals Ltd

P: 022-4031 8111

E: investing@fredungroup.com

Registered Office

'Urmi Estate', 11th Floor,
Ganpatrao Kadam Marg, Lower Parel
(W), Mumbai – 400 013
Tel. No.: +91 22 4031 8111

Runjhun Jain/Sonia Keswani

Ernst & Young LLP

M: 98207 20993 / 80173 93854

E: runjhun.jain1@in.ey.com / sonia.keswani@in.ey.com

Corporate Office

'Urmi Estate', 11th Floor,
Ganpatrao Kadam Marg, Lower Parel
(W), Mumbai – 400 013
Tel. No.: +91 22 4031 8111

Disclaimer:

This press release may include statements of future expectations and other forward-looking statements based on management's current expectations and beliefs concerning future developments and their potential effects upon Fredun and its subsidiaries/associates. These forward-looking statements involve known or unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in such statements. Forward-looking statements are provided to allow potential investors the opportunity to understand management's beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them. Important factors that could cause actual results to differ materially from our expectations include, amongst other: general economic and business conditions in India, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, change in laws and regulations that apply to pharmaceuticals, increasing competition in and changes in political conditions in India. Neither Fredun, nor our Directors, or any of our subsidiaries/associates assume any obligation to update any particular forward-looking statement contained in this release. The Company undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.